肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版)

Chinese Expert Consensus on Management of Thrombocytopenia in Cancer Patients with Liver Injury(2022 Edition)

血小板减少症和肝损伤是肿瘤患者常见且严重的临床问题。肿瘤合并肝损伤患者血小板减少症(thrombocytopenia in cancer patients with liver injury,TCLI)的病因更加复杂,但常见于肝损伤和肿瘤治疗。肿瘤治疗所致血小板减少症的管理已逐渐形成规范,肝损伤相关血小板减少症随着相关药物的获批上市,管理日益明晰。但肿瘤合并肝损伤患者血小板减少症的管理仍是空白,血小板减少症和肝损伤的叠加进一步增加了肿瘤治疗的难度。为此,中国抗癌协会肿瘤支持治疗专业委员会组织专家对文献进行分析和讨论,形成肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版),以指导临床实践。

Thrombocytopenia and liver injury are common and serious clinical problems in cancer patients.The etiology of thrombocytopenia in cancer patients with liver injury(TCLI)is complicated,which is common in liver injury and tumor treatment.The management of cancer therapy-induced thrombocytopenia has gradually become standardized,and the management of liver injury-associated thrombocytopenia is becoming clear with the approval and marketing of relevant drugs.However,the management of TCLI is still blank,and the superposition of thrombocytopenia and liver injury further increases the difficulty of cancer treatment.Therefore,the Committee of Neoplastic Supportive-care,China Anti-Cancer Association organizes experts to analyze and discuss relevant literatures to form a Chinese expert consensus on the management of thrombocytopenia in cancer patients with liver injury(2022 Edition)to guide clinical practice.